Exenatide diabetes drug injectors

Exenatide diabetes drug injectors

C038/7376 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 50.2MB

Downloadable file size: 3.4MB

Price image Pricing

Please login to use the price calculator


Restrictions: Editorial use only

Caption: Exenatide diabetes drug injectors. Designed to be injected under the skin (subcutaneously), this drug has been available since 2005. It is used to treat type 2 diabetes mellitus, and aids the body in controlling the levels of glucose in the blood. It is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) and is classed as an incretin mimetic (mimicking metabolic hormones that control glucose levels). These injectors contain the Bydureon version of the drug, available since 2012 and injected once per week. This drug is marketed by the AstraZeneca pharmaceutical company.

Release details: Model release not required. Property release not required.

Keywords: 4, astrazeneca, bydureon, diabetes, diabetes mellitus, diabetic, drug, endocrinology, exenatide, four, glp-1 receptor agonist, glucagon-like peptide-1 receptor agonist, glucose control, hormonal, hormone, hormones, incretin mimetic, injector, injectors, medical, medicine, no-one, nobody, pharmaceutical, pharmaceutics, pharmacological, pharmacology, quartet, still life, studio shot, syringe, syringes, technological, technology, treatment, type 2

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.